Navigation Links
Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
Date:6/2/2009

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended and restated its "Modified Dutch Auction" tender offer to a fixed price tender offer for any and all of the approximately $118.9 million outstanding principal amount of five series of its convertible notes (the "Notes"). In addition, rather than a single offer for a combined aggregate principal amount of Notes, the Company is now offering to exchange, in separate concurrent offers as set forth below (each, an "Exchange Offer" and together, the "Exchange Offers"), shares of Common Stock and cash for any and all of its:

    (i)   $55,150,000 aggregate outstanding principal amount of 4% Convertible
          Senior Subordinated Notes due 2010;

    (ii)  $23,000,000 aggregate outstanding principal amount of 5.75%
          Convertible Senior Notes due 2011;

    (iii) $7,000,000 aggregate outstanding principal amount of 6.75%
          Convertible Senior Notes due 2010;

    (iv)  $33,458,000 aggregate outstanding principal amount of 7.5%
          Convertible Senior Notes due 2011; and

    (v)   $335,000 aggregate outstanding principal amount of 9.0% Convertible
          Senior Notes due 2012.

Under the Exchange Offers, CTI is offering to exchange (i) $134.50 cash, and (ii) 458 shares of its Common Stock for each $1,000 principal amount of Notes validly tendered and not withdrawn in each Exchange Offer (the "Exchange Consideration"). The Exchange Consideration will be the same for each Exchange Offer. Accrued and unpaid interest to, but excluding, the settlement date on Notes validly tendered and not withdrawn in the Exchange Offers will be paid in cash.

As a result of the amendment and restatement, the Exchange Offers have been extended and will now expire at 5:00 p.m., New York City time, on Tuesday, June 16, 2009, unless the Exchange Offers
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... the leading,management consulting firm specializing in the pharmaceutical ... been appointed Chief,Operating Officer. His former role at ... the firm,s Brand Management Practice will be assumed,by ... new senior executive management role for Mr. Naeymi-Rad ...
... the leading,management consulting firm specializing in the pharmaceutical ... been appointed Senior,Vice President and head of the ... who was recently promoted to Chief,Operating Officer at ... member of the Brand Management Practice,since joining the ...
... 7 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation,(TSX: OBP; ... products, today announced that the results of ... to,eliminate Pseudomonas aeruginosa will be published in ... article has been e-published ahead of the ...
Cached Biology Technology:Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 2Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 3Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance 2Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study 2Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study 3
(Date:8/19/2014)... born with neonatal abstinence syndrome (NAS) secondary to ... going through withdrawal than others, but the underlying ... epigenetic (when genes are turned on or off) ... researchers at Boston University School of Medicine (BUSM) ... of its kind study to identify some of ...
(Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
(Date:8/19/2014)... San Antonio and The University of Texas at San ... $750,000 in grants through the San Antonio Life Sciences ... is a model of how a general academic institution ... for greater research and graduate education. , The Innovation ... health issues and diseases of global impact. Funding will ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... techniques of computer engineering to a mechanistic diagram describing ... of researchers in Switzerland has been able to tease ... the crucial cross-talk between cellular signaling pathways takes place ... The novel in silico model is described in a ...
... Cancer Institute have shown in a laboratory study that ... the damage caused by a form of muscular dystrophy. ... and Development, the researchers demonstrated that manipulating a genetic ... mice with Duchenne muscular dystrophy, slowing the disease-associated muscle ...
... new vaccine delivery system using microspheres of a biodegradable polymer ... some cases, but also appears to stimulate an immune response ... University report their findings today at the ASM Biodefense and ... producing antibodies that block entry into the cell. In ...
Cached Biology News:Executable biology -- Computer science sheds light on animal development 2Switching genes to overdrive improves muscular dystrophy symptoms in mice 2Biodegradable microspheres deliver time release vaccines, stimulate different immune response 2
... coli strain containing an overproducing clone of ... Transcriptase catalyzes the polymerization of DNA using ... copies of large mRNAs, >10 kb, may ... much lower RNase H activity than AMV ...
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
Biology Products: